Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | IL2 | P60568 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | CCKBR | P32239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25233657 | 0.91 | TTR (0.44) | TTRIL2FOLH1PLGXIAP | |
| SCHEMBL31681630 | 0.90 | TTR (0.40) | TTRIL2FOLH1DGAT1 | |
| SCHEMBL29351004 | 0.88 | TTR (0.46) | TTRIL2FOLH1PLGDGAT1 | |
| SCHEMBL25240430 | 0.85 | TTR (0.38) | TTRIL2FOLH1PLGXIAP | |
| SCHEMBL12342504 | 0.83 | TTR (0.44) | TTRIL2FOLH1PLGCCKBR | |
| SCHEMBL20016562 | 0.83 | TTR (0.45) | TTRIL2FOLH1PLGDGAT1 | |
| SCHEMBL24335147 | 0.82 | TTR (0.43) | TTRIL2FOLH1PLGDGAT1 | |
| SCHEMBL25204552 | 0.82 | TTR (0.46) | TTRIL2FOLH1PLGDGAT1 | |
| SCHEMBL26412265 | 0.81 | TTR (0.42) | TTRIL2FOLH1PLGOPRM1 | |
| SCHEMBL12342513 | 0.80 | OPRK1 (0.39) | TTRIL2FOLH1PLGCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | PRELUDE THERAPEUTICS INCORPORATED | 2025-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | CRBN, RBX1, SMARCE1 | TTR 4081/4885IL2 4840/4885FOLH1 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.